Form 4: Aclaris CMO Granted Significant Equity Awards

Aclaris Therapeutics' Chief Medical Officer, Jesse Wayne Hall, received significant equity awards including restricted stock units and stock options.

Summary

• Jesse Wayne Hall, Chief Medical Officer of Aclaris Therapeutics, Inc. (ACRS), was granted equity awards on February 2, 2026.
• The awards include 98,100 Restricted Stock Units (RSUs) and 343,300 Employee Stock Options.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs vest in four equal installments on the first, second, third, and fourth anniversaries of February 2, 2026, contingent on continuous service.
• The Employee Stock Options have an exercise price of $3.61 per share and expire on February 1, 2036.
• The stock options become exercisable with respect to 25% of the shares vesting in four equal installments on the first, second, third, and fourth anniversaries of February 2, 2026, also subject to continuous service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies strong alignment between executive incentives and shareholder value, which is generally favorable for corporate governance and long-term strategy.

Positives

• The grant of substantial equity awards to the Chief Medical Officer aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The vesting schedule, tied to continuous service over four years, indicates a commitment from the executive to the company's future.

Future Outlook

The equity awards, with their multi-year vesting schedules, indicate a long-term commitment from the Chief Medical Officer to Aclaris Therapeutics, Inc. and its future performance. The potential for future share ownership and exercise of options provides a forward-looking incentive for the executive.

Industry Context

StockSavvy.ai notes that granting equity awards, such as restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries for executive compensation. This approach is widely used to attract, retain, and motivate key personnel by aligning their financial interests with the long-term success and share price performance of the company.

Comparison to Industry Standards

• Equity compensation packages for Chief Medical Officers in the biotech sector typically include a mix of restricted stock and stock options, similar to this grant.
• The four-year vesting schedule is a common industry standard designed to ensure long-term executive retention and commitment, comparable to practices at companies like Regeneron Pharmaceuticals or Vertex Pharmaceuticals for their senior executives.

Stakeholder Impact

• Shareholders: The equity awards align the Chief Medical Officer's financial incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.

Next Steps

• The Restricted Stock Units and Employee Stock Options will vest in four equal annual installments, commencing on February 2, 2027, subject to Jesse Wayne Hall's continuous service.

Key Dates

Keywords

Aclaris Therapeutics, ACRS, Form 4, Insider Transaction, Equity Award, Stock Options, Restricted Stock Units, Jesse Wayne Hall, Chief Medical Officer, Executive Compensation